Antimicrobial Resistance in Hospitalized Cancer Patients
Author Information
Author(s): Vikas Gupta, Michael J. Satlin, Kalvin Yu, Yehoda M. Martei, Lillian Sung, Lars F. Westblade, Scott C. Howard, ChinEn Ai, Diane C. Flayhart
Primary Institution: Becton, Dickinson and Company
Hypothesis
What is the rate of antimicrobial resistance (AMR) in hospitalized patients with cancer compared to those without cancer?
Conclusion
AMR rates for certain key pathogens were 1.5–2 times greater in hospitalized cancer patients compared to hospitalized noncancer patients.
Supporting Evidence
- AMR pathogen rates were higher in cancer patients than patients without cancer for most pathogen groups.
- The percentage of nonsusceptible isolates was lower in patients with cancer for most pathogens except for ESBL producers and vancomycin-resistant enterococci.
- AMR rates were significantly higher in cancer patients across all culture sources except for skin/wound for MRSA.
Takeaway
Cancer patients are more likely to have infections that are hard to treat because the germs are resistant to antibiotics, making them sicker than non-cancer patients.
Methodology
This study was a retrospective, cross-sectional evaluation of antimicrobial resistance in hospitalized adult patients across 168 US healthcare facilities from April 2018 to December 2022.
Potential Biases
The retrospective nature of the study and reliance on existing database data may introduce bias.
Limitations
The study's findings may not be applicable to all hospitals in the US due to the sample being from 168 hospitals, and it did not evaluate the type or stage of cancer.
Participant Demographics
The study included hospitalized adult patients, with 6.4% being cancer patients and 93.6% noncancer patients.
Statistical Information
Confidence Interval
95% CI [1.84, 2.07]
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website